Online inquiry

IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14896MR)

This product GTTS-WQ14896MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets stx2 A-subunit gene. The antibody can be applied in hemolytic-uremic syndrome (HUS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq WP_001367518.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID Q8VLD2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14896MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7180MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ10291MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LGT209
GTTS-WQ154MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ112MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 11F8
GTTS-WQ7341MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FPA-150
GTTS-WQ9000MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMA-638
GTTS-WQ7387MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GA101
GTTS-WQ14423MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RO 24-7375
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW